Abstract
The aetiology of psychotic illnesses, in particular schizophrenia, remains elusive; many theories have been put forward but to date there is no all encompassing and satisfactory hypothesis [1]. The therapeutic effects of antipsychotic drugs are generally considered to be associated with blockade of dopamine receptors, especially dopamine D2 receptors [2,3]. In spite of their undeniable clinical usefulness treatment of psychotic patients with these antipsychotic drugs is often accompanied by unwanted side-effects. Acute extrapyramidal syndromes (EPS) are most prominent and may during long-term treatment be followed by irreversible tardive dyskinesia. In addition, some patients do not respond to treatment with the antipsychotic drugs that are available today. For these and other reasons the search for better antipsychotic drugs with improved clinical efficacy and/or less disturbing side-effects continues. Increasingly attention is being focused on other dopamine receptor subtypes than the dopamine D2 receptor, e.g., D1 D3, and D4 receptors, but also serotonin receptor subtypes, sigma receptors, and glutamate receptors [4]. One of the hypotheses concerning the pathophysiology of schizophrenia is the involvement of both dopamine and serotonin neurotransmitter systems [5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681–90.
Creese I, Burt DR, Snyder SH. Dopamine receptor binding - clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481–3.
Seeman P, Lee T, Chsu-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717–9.
Meltzer HY, editor. Novel Antipsychotic Drugs. New York: Raven Press, 1992.
Kahn RS, Davidson M, editors. Serotonin, dopamine and their interactions in schizophrenia. Psychopharmacol 1993; 112 (suppl 1).
De Boer Th, Berendsen H, Broekkamp CLE, Vrijmoed-de Vries MC, Vos RME, Tonnaer JADM, Van Delft AML. Org 5222: antipsychotic, dopamine D2 receptor antagonist, 5-HT2 receptor antagonist. Drugs of the Future 1993; 18:117–23.
Tonnaer JADM, Room P, Van Delft AML, Farde L, Vrijmoed-de Vries MC, Sitsen JMA. Pharmacological and clinical studies with the potential antipsychotic Org 5222. VIIth C.I.N.P. Congress, Kyoto, 1990, Abstract O-13-3-7.
Sitsen JMA, Vrijmoed-de Vries MC. Org 5222 - Preliminary clinical results. In: Meltzer HY, editor. Novel Antipsychotic Drugs. New York: Raven Press, 1992: 15–8.
Finnish-Norwegian Org 5222 Fixed Dose Range Study Group. Results of a placebo-controlled fixed-dose range study with a potential antipsychotic drug: Org 5222. In preparation.
Nordström A-L, Farde L, Pauli S, Litton J-E, Halldin C. PET-analysis of central [11C]raclopride in healthy young adults and schizophrenic patients - reliability and age effects. Human Psychopharmacol 1992;7:157–165.
Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538–44.
Organon, Data on file.
Farde L, Nordström A-L, Nyberg S, Halldin C, Sedvall G. D1 -, D2, and 5HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55[9,suppl B]:67–69.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Sitsen, J.M.A., Farde, L. (1995). PET Studies in the Early Clinical Development of a New Antipsychotic. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_6
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive